Diazepam

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Diazepam
Generic name
DIAZEPAM
Manufacturer
Hikma Pharmaceuticals USA Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
9e85abed-1a8b-4762-a31f-f2c7f196b8af
SPL ID
6d097388-f2e0-4bd4-9faf-1b6b9b949d54
Version
9
Effective date
2026-10-01
Source export date
2026-11-13
Source partition
2
Source file
https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:32:06
Harmonized routes table
Harmonized routes
ORAL

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 )] . • The use of benzodiazepines, including diazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing diazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction [see Warnings and Precautions ( 5.2 )] . • The continued use of benzodiazepines, including diazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of diazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.3 )] . WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS See full prescribing information for complete boxed warning. • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. ( 5.1 , 7.1 ) • The use of benzodiazepines, including diazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing diazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction. ( 5.2 ) • Abrupt discontinuation or rapid dosage reduction of diazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage. ( 2.3 , 5.3 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 2 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS • Central Nervous System (CNS) Depression: Caution patients against engaging in hazardous occupations or activities requiring complete mental alertness (e.g., operating machinery or driving a motor vehicle). Avoid alcohol and use other medications that produce CNS depression with caution ( 5.4 , 7.2 ) • Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behavior ( 5.5 ) • Worsening of Preexisting Depression: Monitor for worsening of preexisting depression ( 5.6 ) • Paradoxical Reactions: Gradually discontinue diazepam if paradoxical reactions occur ( 5.7 ) • Respiratory Depression and Apnea: Use with caution in patients with impaired respiratory function related to concurrent disease process. Consider discontinuing diazepam if signs and symptoms of respiratory depression or apnea occur in any patient ( 5.8 ) • Glaucoma: Can increase intraocular pressure in patients with glaucoma. May be used in patients with open-angle glaucoma only if receiving appropriate therapy ( 4 , 5.9 ) • Neonatal Sedation and Withdrawal Syndrome: Diazepam use during pregnancy can result in neonatal sedation and/or neonatal withdrawal syndrome. ( 5.10 , 8.1 ) 5.1 Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including diazepam, and opioids may result in profound sedation, respiratory depression, coma, and death [see Drug Interactions ( 7.1 )] . Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe diazepam concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of diazepam than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking diazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response. Advise both patients and caregivers about the risks of respiratory depression and sedation when diazepam is used with opioids. 5.2 Abuse, Misuse, and Addiction The use of benzodiazepines, including diazepam, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see Drug Abuse and Dependence ( 9.2 )] . Before prescribing diazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of diazepam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of diazepam along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate. 5.3 Dependence and Withdrawal Reactions To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage (a patient-specific plan should be used to taper the dose) [see Dosage and Administration ( 2.3 )] . Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines, including diazepam, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of diazepam after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) [see Drug Abuse and Dependence ( 9.3 )] . Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months [see Drug Abuse and Dependence ( 9.3 )] . 5.4 Central Nervous System Depression Benzodiazepines, including diazepam, may produce central nervous system (CNS) depression. Caution patients receiving diazepam against engaging in hazardous occupations or activities requiring complete mental alertness (e.g., operating machinery or driving a motor vehicle). Alcohol should be avoided and medications that produce CNS depression should be used with caution during treatment with diazepam [see Drug Interactions ( 7.2 )] . 5.5 Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including diazepam, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table 2 shows absolute and relative risk by indication for all evaluated AEDs. Table 2: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis Indication Placebo Patients with Events Per 1,000 Patients Drug Patients with Events Per 1,000 Patients Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients Risk Differences: Additional Drug Patients with Events Per 1,000 Patients Epilepsy 1.0 3.4 3.5 2.4 Psychiatric 5.7 8.5 1.5 2.9 Other 1.0 1.8 1.9 0.9 Total 2.4 4.3 1.8 1.9 The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing diazepam or any other AED must balance the risk of suicidal thoughts or behaviors with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. 5.6 Worsening of Preexisting Depression Benzodiazepines, including diazepam, may worsen preexisting depression [see Warnings and Precautions ( 5.5 )] . Monitor patients for worsening of preexisting depression. Appropriate precautions (e.g., limiting the total prescription size) should be considered. 5.7 Paradoxical Reactions Paradoxical reactions, such as aggression, agitation, anger, irritability, psychoses, hallucinations, anxiety, nightmares, and increased muscle spasticity have been reported during benzodiazepine use [see Adverse Reactions ( 6 )] . These reactions are more likely to occur in pediatric and geriatric patients. Gradually discontinue diazepam if paradoxical reactions occur [see Dosage and Administration ( 2.3 )] . 5.8 Respiratory Depression and Apnea Use of benzodiazepines, including diazepam, either alone or in combination with other CNS depressants, may lead to potentially fatal respiratory depression [see Warnings and Precautions ( 5.4 )] . In patients with impaired respiratory function treated with benzodiazepines, respiratory depression and apnea have been reported. Use diazepam with caution in patients with impaired respiratory function related to a concurrent disease process [see Use in Specific Populations ( 8.7 )] . If signs and symptoms of respiratory depression or apnea occur in any patient, consider discontinuing diazepam. 5.9 Glaucoma Benzodiazepines, including diazepam, can increase intraocular pressure in patients with glaucoma. Diazepam may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. Diazepam is contraindicated in patients with acute narrow-angle glaucoma. 5.10 Neonatal Sedation and Withdrawal Syndrome Maternal use of diazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Monitor neonates exposed to diazepam during pregnancy or labor for signs of sedation and monitor neonates exposed to diazepam during pregnancy for signs of withdrawal; manage these neonates accordingly [see Use in Specific Populations ( 8.1 )] .

warnings and cautions table

<table styleCode="Noautorules" width="100%"> <caption>Table 2: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis</caption> <col width="20%"/> <col width="20%"/> <col width="20%"/> <col width="20%"/> <col width="20%"/> <tbody> <tr> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">Indication</content> </paragraph> </td> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">Placebo Patients with Events Per 1,000 Patients</content> </paragraph> </td> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">Drug Patients with Events Per 1,000 Patients</content> </paragraph> </td> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</content> </paragraph> </td> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">Risk Differences: Additional Drug Patients with Events Per 1,000 Patients</content> </paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>Epilepsy</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>1.0</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>3.4</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>3.5</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>2.4</paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>Psychiatric</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>5.7</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>8.5</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>1.5</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>2.9</paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>Other</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>1.0</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>1.8</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>1.9</paragraph> </td> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0.9</paragraph> </td> </tr> <tr> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>Total</paragraph> </td> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>2.4</paragraph> </td> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>4.3</paragraph> </td> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>1.8</paragraph> </td> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>1.9</paragraph> </td> </tr> </tbody> </table>

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the labeling: • Risks from Concomitant Use with Opioids [see Warnings and Precautions ( 5.1 )] • Abuse, Misuse, and Addiction [see Warnings and Precautions ( 5.2 )] • Dependence and Withdrawal Reactions [see Warnings and Precautions ( 5.3 )] • Central Nervous System Depression [see Warnings and Precautions ( 5.4 )] • Suicidal Behavior and Ideation [see Warnings and Precautions ( 5.5 )] • Worsening of Preexisting Depression [see Warnings and Precautions ( 5.6 )] • Paradoxical Reactions [see Warnings and Precautions ( 5.7 )] • Respiratory Depression and Apnea [see Warnings and Precautions ( 5.8 )] • Glaucoma [see Warnings and Precautions ( 5.9 )] • Neonatal Sedation and Withdrawal Syndrome [see Warnings and Precautions ( 5.10 )] The following adverse reactions associated with the use of diazepam were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions most commonly reported were drowsiness, fatigue, muscle weakness, and ataxia. The following adverse reactions have also been reported: Blood and lymphatic disorders: neutropenia Eye disorders: blurred vision, diplopia Gastrointestinal disorders: changes in salivation, including dry mouth and hypersalivation, gastrointestinal disturbances, constipation, nausea Hepatobiliary disorders: jaundice Injury, poisoning and procedural complications: falls and fractures. The risk is increased in those taking concomitant CNS depressants (including alcohol) and in geriatric patients. Investigations: elevated transaminases and alkaline phosphatase Nervous system disorders: vertigo, dizziness, dysarthria, tremor, headache Changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after diazepam therapy. Psychiatric disorders: disorientation, confusional state, decreased alertness, inappropriate behavior, emotional and mood disturbances, depression, acute hyperexcited states, hyperactivity, restlessness, stimulation, anxiety, nervousness, aggressiveness, agitation, anger, hostility, irritability, psychoses, delusions, hallucinations, insomnia, sleep disturbances, abnormal dreams, nightmares Anterograde amnesia has been reported, with the risk increasing at higher dosages. Amnestic effects may be associated with inappropriate behavior. Skin and subcutaneous tissue disorders: skin reactions Urogenital disorders: incontinence, changes in libido, urinary retention Vascular disorders: hypotension Most common adverse reactions are drowsiness, fatigue, muscle weakness, and ataxia ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.